Biocon Limited
1,421words
0turns
0analyst exchanges
0executives
Key numbers — 28 extracted
rs,
, 2025 To, The Secretary BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati
3
%
₹ Cr Generics Biosimilars Research Services Revenue from Operations Total Revenue Core EBITDA3 % Margin R&D (Net) % of Revenue (Ex. Syngene) EBITDA % Margin Profit Before Tax (Before except
₹286 crore
Tacrolimus to China, partner expected to initiate commercialization in Q1FY26 R&D investments at ₹286 crores, ~9.5% of segment revenues for FY25 Our peptide portfolio, esp. GLP-1s will be the key drivers fo
9.5%
China, partner expected to initiate commercialization in Q1FY26 R&D investments at ₹286 crores, ~9.5% of segment revenues for FY25 Our peptide portfolio, esp. GLP-1s will be the key drivers for future
31%
evenue 1,048 Core EBITDA % of Total Revenue R&D % of Revenue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39
8%
,048 Core EBITDA % of Total Revenue R&D % of Revenue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% Y
23%
e EBITDA % of Total Revenue R&D % of Revenue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ%
21%
nue R&D % of Revenue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ% 46 111 53 219 27 14
9%
% of Revenue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ% 46 111 53 219 27 14 164 5
12%
venue EBITDA % of Total Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ% 46 111 53 219 27 14 164 530 In ₹
14%
Revenue 326 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ% 46 111 53 219 27 14 164 530 In ₹ Cr Operating Revenue Co
11%
26 31% 83 8% 243 23% Q4 FY24 718 155 21% 65 9% 92 12% Q3 FY25 686 102 14% 73 11% 39 5% YoY% QoQ% 46 111 53 219 27 14 164 530 In ₹ Cr Operating Revenue Core EBITDA
Advertisement